Susan Margaret Sundström
Corporate Officer/Principal bei The University of Southampton
Profil
Susan Margaret Sundström is currently a Principal at The University of Southampton.
Previously, she was a Non-Executive Director at Synairgen Plc from 2003 to 2009, and a Non-Executive Director at Karus Therapeutics Ltd.
She also held a position as a Principal at AstraZeneca PLC.
Aktive Positionen von Susan Margaret Sundström
| Unternehmen | Position | Beginn |
|---|---|---|
| The University of Southampton | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Susan Margaret Sundström
| Unternehmen | Position | Ende |
|---|---|---|
| SYNAIRGEN PLC | Direktor/Vorstandsmitglied | 03.09.2009 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SYNAIRGEN PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
